Our solutions
Pipeline
At Chiesi, our portfolio and pipeline are focused on developing and bringing to market innovative pharmaceutical solutions that improve quality of people’s life, with a strong focus on our core therapeutic areas: respiratory diseases, rare and ultra-rare diseases, neonatology, special and primary care.
This strategic choice allows us to continue expanding and strengthening our pipeline with studies that promise significant advancements for the future of our company, while also offering new opportunities for patients with unmet medical needs who currently lack therapeutic options for their conditions.
Respiratory diseases
| Indication / Disease | Active Principle | Formulation | Region | Phase | Alliance / Partnership |
|---|---|---|---|---|---|
| Asthma, COPD | BDP + FF | pMDI, DPI | EU | Post-approval | - |
| Asthma, COPD | BDP + FF + GB | pMDI, DPI | EU | Post-approval | - |
| Asthma, COPD | BDP + FF + GB | pMDI | US | Phase 3 | - |
| Asthma | BDP + FF + GB | DPI | Ex US | Phase 3 | - |
| Asthma, COPD | BDP + FF + GB | pMDI with HFA 152a (Carbon Minimal Inhaler) | Global | Phase 3 | - |
| Asthma, COPD | BDP + FF | pMDI with HFA 152a (Carbon Minimal Inhaler) | Global | Phase 3 | - |
| Asthma | BDP | pMDI with HFA 152a (Carbon Minimal Inhaler) | Selected countries in EU and Ex-EU | Phase 3 | - |
| Bronchiectasis | DDP1i | Oral | Ex - China | Phase 3 | Haisco |
| Bronchiectasis | NEi | DPI | Global | Phase 2 | - |
| Idiopathic pulmonary fibrosis (IPF) | Zampilimab (anti TG-2) | Intravenous (IV) | - | Phase 2 | UCB |
| Idiopathic pulmonary fibrosis (IPF) | DDRi | DPI | Global | Phase 1 | - |
Rare diseases
| Indication / Disease | Active Principle | Formulation | Region | Phase | Alliance / Partnership |
|---|---|---|---|---|---|
| Alpha-mannosidosis | Velmanase alfa-tycv | Lyophilized sterile powder for reconstitution with 5ml sterile water for infusion | EU, US | Post-approval | - |
| Alpha-mannosidosis | - | - | Global | Preclinical | Key2Brain |
| Krabbe disease | - | - | Global | Preclinical | Key2Brain |
| Nephropathic cystinosis | Cysteamine bitartrate | Gastro-resistant hard capsules | EU, US | Post-approval | Amgen |
| Fabry disease | Pegunigalsidase alfa-iwxj | IV Solution | EU, UK, US | Post-approval | Protalix Biotherapeutics |
| Fabry disease - pediatric | Pegunigalsidase alfa-iwxj | IV Solution | Global | Phase 2/3 | Protalix Biotherapeutics |
| Fabry disease | Pegunigalsidase alfa-iwxj | IV Solution | Japan | Phase 2/3 | Protalix Biotherapeutics |
| Other inborn errors of metabolism diseases | - | - | Global | Preclinical | Aliada |
| Leber’s Hereditary Optic Neuropathy (LHON) | Idebenone | Flm-coated tablets | EU | Post-approval | - |
| Generalized Lipodystrophy | Metreleptin | Injection | Global | Post-approval | - |
| Partial Lipodystrophy | Metreleptin | Injection | EU | Post-approval | - |
| Partial Lipodystrophy | Metreleptin | Injection | US | Phase 3 | - |
| Acromegaly | Octreotide | Gastro-resistant hard capsules | US | Post-approval | - |
| Homozygous Familial Hypercholesterolemia (HoFH) | Lomitapide | Capsules | EU, US | Post-approval | - |
| Primary Hyperoxalurlia type 1 | - | - | Global | Phase 1/2 | Arbor Biotechnologies |
| Epidermolysis Bullosa (EB) | Birch triterpenes | Topical gel | EU, US | Post-approval | - |
| Epidermolysis Bullosa (EB) | Birch triterpenes | Topical gel | Japan | Phase 3 | - |
| Thalassemia | Deferiprone | Tablets oral solution | EU, US | Post-approval | - |
| Sickle Cell Disease or Other Anaemias | Deferiprone | Tablets oral solution | US | Post-approval | - |
| Adenosine Deaminase - Severe Combined Immune Deficiency | Elapegademase-lvlr | Injection | JP, US | Post-approval | - |
| Other rare diseases | - | - | Global | Preclinical | Arbor Biotechnologies |
Special care and Primary care
| Indication / Disease | Active Principle | Formulation | Region | Phase | Alliance / Partnership |
|---|---|---|---|---|---|
| Neonatal RDS treatment | Poractant alfa | Endotracheopulmonary Instillation sterile Suspension | - | Post-approval | - |
| Treatment of primary apnoea of premature newborns | Caffeine Citrate | Solution for infusion, oral solution | - | Post-approval | - |
| Reduction of blood pressure when oral therapy is not feasible or in perioperative settings | Clevidipine | Emulsion | - | Post-approval | - |
| Anti-platelet; reducing risk of thrombotic cardiovascular events undergoing percutaneous coronary intervention (PCI) | Cangrelor | Lyophilized powder | US, EU | Post-approval | - |
| Prophylaxis of transplant rejection in adult kidney or liver allograft recipients | Tacrolimus | Prolonged-release tablets | - | Post-approval | Veloxis |
| Prevention of bronchopulmonary dysplasia (BPD) | IGF-1 Biologic | Sterile solution for infusion | - | Phase 2b | Oak Hill Bio |
| Treatment of intestinal malabsorption in preterm infants | Insulin | Oral solution | - | Phase 3 | Elgan |